Institute for Artificial Intelligence in Medicine, University Hospital Essen, Essen, Germany.
Department of Urology, University Hospital Essen, Essen, Germany.
Ann Oncol. 2023 Jun;34(6):507-519. doi: 10.1016/j.annonc.2023.03.001. Epub 2023 Mar 15.
Radiotheranostics is a field of rapid growth with some approved treatments including I for thyroid cancer, Ra for osseous metastases, Lu-DOTATATE for neuroendocrine tumors, and Lu-PSMA (prostate-specific membrane antigen) for prostate cancer, and several more under investigation. In this review, we will cover the fundamentals of radiotheranostics, the key clinical studies that have led to current success, future developments with new targets, radionuclides and platforms, challenges with logistics and reimbursement and, lastly, forthcoming considerations regarding dosimetry, identifying the right line of therapy, artificial intelligence and more.
放射性药物治疗是一个快速发展的领域，已有一些批准的治疗方法，包括用于甲状腺癌的 I，用于骨转移的 Ra，用于神经内分泌肿瘤的 Lu-DOTATATE，以及用于前列腺癌的 Lu-PSMA（前列腺特异性膜抗原），还有更多正在研究中。在这篇综述中，我们将涵盖放射性药物治疗的基础知识、导致当前成功的关键临床研究、新靶标、放射性核素和平台的未来发展、物流和报销方面的挑战，以及最后关于剂量学、确定正确的治疗线、人工智能等方面的未来考虑。
